Advertisement

(http://www.givenimaging.com)

Given Imaging Ltd. (NASDAQ: GIVN), a world leader in specialty GI

products and pioneer of capsule endoscopy, today announced that the

Company will participate in multiple events in honor of National

Colorectal Cancer Awareness Month. Throughout the month of March,

Given Imaging will be taking part in several national initiatives to

raise awareness about colorectal cancer, the third leading cause of

cancer-related deaths in the United States, and about the importance

of colorectal cancer screening.

Today, Given Imaging employees in the Duluth, Georgia, and Los

Angeles, California offices will be dressing in blue to support the

Global Colon Cancer Alliance's Dress in Blue Day. The nationwide

program aims to bring attention to colon cancer and to celebrate the

courage of those affected by this disease.

"Colorectal cancer affects hundreds of thousands of lives each year

and the National Colorectal Cancer Awareness Month is therefore an

important initiative that brings attention to the importance of

colorectal cancer screening, prevention and research," said Homi

Shamir, president and chief executive officer, Given Imaging Ltd. "We

are excited to be engaged in events throughout the month of March to

show Given Imaging's dedication to raising awareness about colorectal

cancer."

Also as a part of National Colorectal Cancer Awareness Month, Given

Imaging is proud to be a sponsor of the 2012 Fight Colorectal Cancer's

Call-on Congress. As a sponsor, Given Imaging will be sending a group

of employees to Washington D.C. to take part in the three-day event

which brings together advocates from across the country to articulate

the message that colorectal cancer is preventable, treatable and

beatable. Advocates are trained on how to openly discuss this deadly

disease with their elected officials and then have the opportunity to

speak with members of Congress about the burden of colon cancer,

national preventative screening initiatives, and the ongoing need for

additional research funding. The final event of the Call-on Congress

campaign, the Sixth Annual Advocate Celebration Dinner -- A United

Voice Behind a Cure, will take place on Wednesday, March 7, 2012 to

celebrate colorectal cancer advocacy and survivorship. For more

information on the Call-on Congress campaign, please visit:

http://fightcolorectalcancer.org/policy/call-on_congress(http://ctt.marketwire.com/?release858298&id1327006&type1&urlhttp%3a%2f%2ffightcolorectalcancer.org%2fpolicy%2fcall-on_congress).

In addition, to raise awareness about the important role family

history plays in preventing colorectal cancer, Given Imaging's

employees will be utilizing several exciting new tools from the

National Colorectal Cancer Roundtable's Family PLZ! Campaign. This

campaign targets people ages 18 to 45 with a message about

understanding family health history, with the goal of increasing

screening adherence. The campaign encourages young people to start

talking to family members about their family history of colorectal

cancer or polyp, spurring young people to take action steps to "search

and share their family's health history," while reiterating the

message that colorectal cancer screening should begin at 50 for those

without a family history. For more information on Family PLZ!, please

visit:

http://familyplz.org/home(http://ctt.marketwire.com/?release858298&id1327009&type1&urlhttp%3a%2f%2ffamilyplz.org%2fhome).

Finally, throughout the month of March, Given Imaging is encouraging

all employees to take part in the company's corporate fundraising

initiative. All money raised during the month of March by employees

will be donated to the Global Colon Cancer Alliance, the oldest and

largest national patient advocacy organization dedicated to ending the

suffering caused by colorectal cancer. For more information on the

Global Colon Cancer Alliance, please visit:

http://www.ccalliance.org/(http://ctt.marketwire.com/?release858298&id1327012&type1&urlhttp%3a%2f%2fwww.ccalliance.org%2f).

Additional information detailing all of Given Imaging's events during

this year's National Colorectal Cancer Awareness Month can be found on

their Facebook page:

http://www.facebook.com/GivenImaging(http://ctt.marketwire.com/?release858298&id1327015&type1&urlhttp%3a%2f%2fwww.facebook.com%2fGivenImaging).

About Colorectal Cancer

Colorectal cancer remains a potentially fatal disease that generally

can be prevented through early detection. Colon cancer occurs in the

large intestine (colon), the lower part of the digestive system, while

rectal cancer occurs in the last 15-20 centimeters of the colon.

Together, they're often referred to as colorectal cancers.

Colon and rectal cancers begin in the digestive system and develop

when cells that line the colon or the rectum become abnormal and grow

exponentially. Most cases of colorectal cancer begin as small,

non-cancerous (benign) clumps of cells called adenomatous polyps. Only

certain kinds of polyps have the potential to become cancerous, and in

most people, colorectal cancers develop slowly over a period of

several years. In the US alone, more than 51,000 people will die from

colorectal cancer in 2010(1).

About Given Imaging Ltd.

Since pioneering the field of capsule endoscopy in 2001, Given Imaging

has become a world leader in GI medical devices, offering health care

providers a range of innovative options for visualizing, diagnosing

and monitoring the digestive system. The company offers a broad

product portfolio including PillCam@ video capsules for the small

bowel, esophagus and colon PillCam@ COLON not approved for use in the

United States, industry-leading ManoScan high-resolution manometry

and Bravo@ wireless and Digitrapper@ pH and impedance products. Given

Imaging is committed to delivering breakthrough innovations to the GI

community and supporting its ongoing clinical needs. Given Imaging's

headquarters are located in Yoqneam, Israel, with operating

subsidiaries in the United States, Germany, France, Japan, Australia,

Vietnam and Hong Kong. For more information, please visit

www.givenimaging.com(http://ctt.marketwire.com/?release858298&id1327018&type1&urlhttp%3a%2f%2fwww.givenimaging.com%2f)

Forward-Looking Statements

This press release contains forward-looking statements within the

meaning of the "safe harbor" provisions of the U.S. Private Securities

Litigation Reform Act of 1995. These forward-looking statements

include, but are not limited to, projections about our business and

our future revenues, expenses and profitability. Forward-looking

statements may be, but are not necessarily, identified by the use of

forward-looking terminology such as "may," "anticipates," "estimates,"

"expects," "intends," "plans," "believes," and words and terms of

similar substance. Forward-looking statements involve known and

unknown risks, uncertainties and other factors which may cause the

actual events, results, performance, circumstances or achievements of

the Company to be materially different from any future events,

results, performance, circumstances or achievements expressed or

implied by such forward-looking statements. Factors that could cause

actual events, results, performance, circumstances or achievements to

differ from such forward-looking statements include, but are not

limited to, the following: (1) our ability to develop and bring to

market new products, (2) our ability to successfully complete any

necessary or required clinical studies with our products, (3) our

ability to receive regulatory clearance or approval to market our

products or changes in regulatory environment, (4) our success in

implementing our sales, marketing and manufacturing plans, (5) the

level of adoption of our products by medical practitioners, (6) the

emergence of other products that may make our products obsolete, (7)

lack of an appropriate bowel preparation materials to be used with our

PillCam COLON capsule, (8) protection and validity of patents and

other intellectual property rights, (9) the impact of currency

exchange rates, (10) the effect of competition by other companies,

(11) the outcome of significant litigation, (12) our ability to obtain

reimbursement for our product from government and commercial payors,

(13) quarterly variations in operating results, (14) the possibility

of armed conflict or civil or military unrest in Israel, (15) the

impact of global economic conditions, (16) our ability to successfully

integrate acquired businesses, (17) changes and reforms in applicable

healthcare laws and regulations, (18) quality issues and adverse

events related to our products, such as capsule retention, aspiration

and failure to attach or detach, bleeding or perforation that could

require us to recall products and impact our sales and net income, and

(19) other risks and factors disclosed in our filings with the U.S.

Securities and Exchange Commission, including, but not limited to,

risks and factors identified under such headings as "Risk Factors,"

"Cautionary Language Regarding Forward-Looking Statements" and

"Operating Results and Financial Review and Prospects" in the

Company's Annual Report on Form 20-F for the year ended December 31,

2010. You are cautioned not to place undue reliance on these

forward-looking statements, which speak only as of the date of this

press release. Except for the Company's ongoing obligations to

disclose material information under the applicable securities laws, it

undertakes no obligation to release publicly any revisions to any

forward-looking statements, to report events or to report the

occurrence of unanticipated events.

(1)

http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics(http://ctt.marketwire.com/?release858298&id1327021&type1&urlhttp%3a%2f%2fwww.cancer.org%2fcancer%2fcolonandrectumcancer%2fdetailedguide%2fcolorectal-cancer-key-statistics)

Advertisement
Advertisement